Talk:Copanlisib

Todos in the drug box
I had found two topics for clarification by appropriate and interested experts: a) the "| licence_US = " did not lead to the correct drugs@fda page, neither for Aliqopa, nor ALIQOPA nor copanlisib. b) the SMILES I copied from the old chembox. However, looking at the drugs chembl page, I found a differently looking SMILES entry. Is this free-base vs. salt related? Which one to use? Wowbagger2 (talk) 14:19, 15 December 2017 (UTC)

As of 2019, Aliqopa is not APPROVED by FDA but it is CONDITIONALLY APPROVED
It has not yet demonstrated it's primary endpoint, but phase 2 analyses of efficacy endpoints were highly promising. The US FDA approval pipeline is starting to conditionally approve some drugs, with the condition being they have to go demonstrate the primary endpoints. This is subtle. But a conditionally approved drug may be removed from the market. — Preceding unsigned comment added by 76.191.127.162 (talk) 15:18, 7 October 2019 (UTC)

Unclear wording
"Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells."

This sounds either like Copansilib is an effective drug against cancerous B-cell or Copansilib is a dangerous drug that may actually help cancerous B-cell and lower the chance of survival. — Preceding unsigned comment added by Akangka (talk • contribs) 01:58, 6 January 2020 (UTC)

USPI wording: "Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines." 2003:E2:4F38:5B00:3DA4:12F9:6CF4:B62D (talk)